Clinical Trial Update: Lidoderm® (Lidocaine Patch 5%) in Diabetic and Idiopathic Neuropathy [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on Lidoderm (lidocaine patch 5%) for diabetic neuropathy and idiopathic peripheral neuropathy; the study status is COMPLETED.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Neuropathy
• Idiopathic Peripheral Neuropathy

Drugs mentioned

• Lidoderm (lidocaine patch 5%)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Diabetes | Phase 4 | Status: COMPLETED